Medicines & Healthcare products Regulatory Agency

MHRA Central Freedom of Information Team
10 South Colonnade
Canary Wharf
London
E14 4PU

foi.request@mhra.gov.uk.

MHRA Website

[redacted]

Our Ref: **FOI2026/00783**

27 July 2026

Dear [redacted]

Thank you for your Freedom of Information (FoI) request received on 18 July. You wrote:

> *Thank you for your response. I have clarified my request and restated it for you below:*
>
> *1) How many of the following types of peptide were seized by the MHRA during in 2024 and 2025?*
> *- Retatrutide*
> *- BPC-157*
> *- GLP-1*
> *- NAD+*
> *- CJC 1295*
> *-Ipamorelin*
>
> *2) How many of the following peptide products were seized by the MHRA in the first 5 months of 2026?*
> *- Retatrutide*
> *- BPC-157*
> *- GLP-1*
> *- NAD+*
> *- CJC 1295*
> *-Ipamorelin*
>
> *3) How many counterfeit peptide products were seized by the MHRA in the following periods?*
> *- the year 2024*
> *- the year 2025*
> *- the first five months of 2026*
>
> *Please let me know if you require any further clarification. Thanks,*

MHRA Response

We confirm that we hold the information you have requested.

We have the following information available in response to questions 1 and 2, figures refer to approximate doses of medicine:

	2024	2025	2026 (to date)
Retatrutide	0	13,400	40,000
BPC-157	0	0	12,000
GLP-1	1,900	1,000	1,400
NAD+	0	0	12,000
CJC 1295	0	0	0
Ipamorelin	0	0	0

For a peptide product to fall within the remit of the MHRA is must first meet the definition of a medicine contained within the Human Medicines Regulations 2012. The assessment of this is done on a case-by-case basis. Not all peptides will necessarily be regarded as medicinal products; it will depend on the circumstances. The 2026 figures for BPC-157 and NAD+ are split evenly as we do not have a full breakdown of how these products are divided, we only have a combined figure of the seizure of about 24,000 doses of BPC-157 and NAD+.

We do not have the data available to answer question 3. The MHRA deals with offences relating to unauthorised or falsified medicines, not counterfeit. The medicine seizures detailed in the above table refer to medicines classified as unauthorised or falsified.

If you have any queries about this letter, please contact us quoting the reference number above.

Yours sincerely,

MHRA Central Freedom of Information Team
Medicines & Healthcare products Regulatory Agency

Your right to complain under the Freedom of Information Act

If you are not happy with this response you may request an internal review by e-mailing foi.request@mhra.gov.uk or by writing to: MHRA Central Freedom of Information Team, 10 South, Colonnade, Canary Wharf, London, E14 4PU

Any request for an internal review must be received by us within 40 working days of the date of this letter. Please note we are not obliged to provide a review if it is requested after more than 40 working days.

If you are not content with the outcome of the internal review, you may apply directly to the Information Commissioner's Office for a decision. Generally, the Commissioner cannot make a decision unless you have exhausted our own complaints procedure. The Information Commissioner can be contacted at: The Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire SK9 5AF.
Website: ICO FOI and EIR complaints or telephone 0303 123 1113.

Re-use of our information
The MHRA information supplied in response to your request is subject to Crown copyright. Information created by the MHRA which is disclosed under the Freedom of Information Act is made available for re-use under the Open Government Licence (OGL) v3.0, except where

this is otherwise stated. There are some restrictions on re-use under the OGL and these can be viewed here:
https://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/